Zai Lab Unveils Promising Preclinical Results for ZL-1503 as Novel Treatment for Moderate-to-Severe Atopic Dermatitis at EAACI Congress 2025

Reuters

06-13

Zai Lab Unveils Promising Preclinical Results for ZL-1503 as Novel Treatment for Moderate-to-Severe Atopic Dermatitis at EAACI Congress 2025

Zai Lab Ltd. has announced promising preclinical data for their bispecific antibody, ZL-1503, aimed at treating moderate-to-severe atopic dermatitis and other conditions driven by IL-13 and IL-31. The data, presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, highlight ZL-1503's ability to simultaneously suppress inflammatory and pruritogenic pathways, offering a potential novel treatment option. The preclinical study demonstrated a favorable safety profile, prolonged half-life, and durable suppression of disease pathways in non-human primates. Zai Lab plans to advance ZL-1503 to IND-enabling studies with an Investigational New Drug $(IND.AU)$ filing expected by the end of 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zai Lab Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250613588431) on June 13, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2543297686"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2543297686\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2543297686?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-13 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2543297686","market":"us","top_or_hot":-1,"title":"Zai Lab Unveils Promising Preclinical Results for ZL-1503 as Novel Treatment for Moderate-to-Severe Atopic Dermatitis at EAACI Congress 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Zai Lab Unveils Promising Preclinical Results for ZL-1503 as Novel Treatment for Moderate-to-Severe Atopic Dermatitis at EAACI Congress 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Zai Lab Ltd. has announced promising preclinical data for their bispecific antibody, ZL-1503, aimed at treating moderate-to-severe atopic dermatitis and other conditions driven by IL-13 and IL-31. The data, presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, highlight ZL-1503's ability to simultaneously suppress inflammatory and pruritogenic pathways, offering a potential novel treatment option. The preclinical study demonstrated a favorable safety profile, prolonged half-life, and durable suppression of disease pathways in non-human primates. Zai Lab plans to advance ZL-1503 to IND-enabling studies with an Investigational New Drug <a href=\"https://laohu8.com/S/IND.AU\">$(IND.AU)$</a> filing expected by the end of 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zai Lab Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250613588431) on June 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zai Lab Unveils Promising Preclinical Results for ZL-1503 as Novel Treatment for Moderate-to-Severe Atopic Dermatitis at EAACI Congress 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZai Lab Unveils Promising Preclinical Results for ZL-1503 as Novel Treatment for Moderate-to-Severe Atopic Dermatitis at EAACI Congress 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-13 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Zai Lab Unveils Promising Preclinical Results for ZL-1503 as Novel Treatment for Moderate-to-Severe Atopic Dermatitis at EAACI Congress 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Zai Lab Ltd. has announced promising preclinical data for their bispecific antibody, ZL-1503, aimed at treating moderate-to-severe atopic dermatitis and other conditions driven by IL-13 and IL-31. The data, presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, highlight ZL-1503's ability to simultaneously suppress inflammatory and pruritogenic pathways, offering a potential novel treatment option. The preclinical study demonstrated a favorable safety profile, prolonged half-life, and durable suppression of disease pathways in non-human primates. Zai Lab plans to advance ZL-1503 to IND-enabling studies with an Investigational New Drug <a href=\"https://laohu8.com/S/IND.AU\">$(IND.AU)$</a> filing expected by the end of 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zai Lab Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250613588431) on June 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250613:nNDL4kcym4:1","article_id":"2543297686","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2543297686","pubTimestamp":1749812433,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Zai Lab Unveils Promising Preclinical Results for ZL-1503 as Novel Treatment for Moderate-to-Severe Atopic Dermatitis at EAACI Congress 2025. Zai Lab Ltd. has announced promising preclinical data for their bispecific antibody, ZL-1503, aimed at treating moderate-to-severe atopic dermatitis and other conditions driven by IL-13 and IL-31. The data, presented at the European Academy of Allergy and Clinical Immunology  Congress 2025 in Glasgow, highlight ZL-1503's ability to simultaneously suppress inflammatory and pruritogenic pathways, offering a potential novel treatment option. The preclinical study demonstrated a favorable safety profile, prolonged half-life, and durable suppression of disease pathways in non-human primates. Zai Lab plans to advance ZL-1503 to IND-enabling studies with an Investigational New Drug  filing expected by the end of 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide ac","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","BK1574":"生物医药B类股","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK1588":"回港中概股","09688":"再鼎医药"},"translate_title":"再鼎医药在2025年EAACI大会上公布了ZL-1503作为中重度特应性皮炎新疗法的有希望的临床前结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09688":0.9},"content_text":"Zai Lab Unveils Promising Preclinical Results for ZL-1503 as Novel Treatment for Moderate-to-Severe Atopic Dermatitis at EAACI Congress 2025\n    \n\n        Zai Lab Ltd. has announced promising preclinical data for their bispecific antibody, ZL-1503, aimed at treating moderate-to-severe atopic dermatitis and other conditions driven by IL-13 and IL-31. The data, presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, highlight ZL-1503's ability to simultaneously suppress inflammatory and pruritogenic pathways, offering a potential novel treatment option. The preclinical study demonstrated a favorable safety profile, prolonged half-life, and durable suppression of disease pathways in non-human primates. Zai Lab plans to advance ZL-1503 to IND-enabling studies with an Investigational New Drug $(IND.AU)$ filing expected by the end of 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zai Lab Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250613588431) on June 13, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}